ArticleScience advances2020
In vivo priming of human mesenchymal stem cells with hepatocyte growth factor-engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 137 citations in OpenAlex.
- Click chemistry-modified cardiomyocytes enhance cardiac contractility and prevent remodeling in ischemia-reperfusion injured hearts.Bioactive materials · 2027Article
- Repairing the Infarcted Heart: Preclinical Outcomes of Cardiac Tissue Engineering.Stem cell reviews and reports · 2026Review
- An overview of recent flexible- and soft-biomaterial applications in myocardial infarction and other cardiovascular diseases.Materials today. Bio · 2026Review
- Biofabrication strategies for engineered constructs in cardiovascular tissue repair.Regenerative therapy · 2026Review
- Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.iScience · 2026Review
- Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling.Advanced healthcare materials · 2026Review
- Hepatocyte growth factor in biosheets promotes autonomous regeneration of cutaneous tissue after transplantation onto a full-thickness skin defect.Materials today. Bio · 2026Article
- Review
- Mammalian mesenchymal stromal cells enhance zebrafish fin regeneration.Cell regeneration (London, England) · 2026Article
- Mesenchymal Stem Cell-derived Exosomes in the Treatment of End-stage Liver Disease.Current stem cell research & therapy · 2026Review
- Cardiac Repair and Mesenchymal Stem Cells: Exploring New Frontiers in Regenerative Medicine.Current cardiology reviews · 2026Review
- Interactions Between Active Matters and Endogenous Fields.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- "Advancing cardiac patch viability and functionality: innovations in scaffold design and cellular optimization".Journal of materials science. Materials in medicine · 2025Review
- Priming Canine Adipose Tissue-Derived Mesenchymal Stem Cells with CBD-Rich Cannabis Extract Modulates Neurotrophic Factors Expression Profile.Veterinary sciences · 2025Article
- Current perspectives on regenerative potential of mesenchymal stem cells in alleviating cardiac injuries: Molecular pathways and therapeutic enhancement.World journal of stem cells · 2025Review
- Reinforcing Stromal Cell Spheroid Through Red-Light Preconditioning for Advanced Vascularization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cardiac Tissue Bioprinting: Integrating Structure and Functions Through Biomimetic Design, Bioinks, and Stimulation.Gels (Basel, Switzerland) · 2025Review
- Therapeutic potential of CD73Histology and histopathology · 2025Review
- An Off-the-Shelf Artificial Proregenerative Macrophage for Pressure Ulcer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Innovative approaches to boost mesenchymal stem cells efficacy in myocardial infarction therapy.Materials today. Bio · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical use of human bone marrow-derived mesenchymal stem cells (BM-MSCs) has been hampered by their poor performance after transplantation into failing hearts. Here, to improve the therapeutic potential of BM-MSCs, we developed a strategy termed in vivo priming in which BM-MSCs are primed in vivo in myocardial infarction (MI)-induced hearts through genetically engineered hepatocyte growth factor-expressing MSCs (HGF-eMSCs) that are encapsulated within an epicardially implanted 3D cardiac patch. Primed BM-MSCs through HGF-eMSCs exhibited improved vasculogenic potential and cell viability, which ultimately enhanced vascular regeneration and restored cardiac function to the MI hearts. Histological analyses further demonstrated that the primed BM-MSCs survived longer within a cardiac patch and conferred cardioprotection evidenced by substantially higher numbers of viable cardiomyocytes in the MI hearts. These results provide compelling evidence that this in vivo priming strategy can be an effective means to enhance the cardiac repair of MI hearts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.